Rallybio
Rallybio is a clinical-stage biotech company committed to delivering groundbreaking therapies for rare diseases, aiming to transform the lives of patients through innovative science, strategic partnerships, and a dedicated team. The company focuses on diseases with well-understood mechanisms and significant unmet medical needs, building a broad pipeline of product candidates in areas such as complement dysregulation, hematology, and metabolic disorders.
Industries
Nr. of Employees
small (1-50)
Rallybio
Products
C5-targeted antibody-mimetic fusion protein (once-weekly, subcutaneous)
A protein fusion construct engineered to inhibit Complement component 5 (C5) intended for complement-mediated diseases; formulated for small-volume, once-weekly subcutaneous self-administration.
C5-targeted PEG-conjugated small protein for intravitreal use
A small protein designed to inhibit C5 and conjugated to polyethylene glycol to extend ocular half-life, intended for intravitreal administration in ophthalmic complement-driven diseases.
Long-acting anti-matriptase-2 monoclonal antibody (subcutaneous)
A long-acting monoclonal antibody designed to inhibit matriptase-2 to increase hepcidin levels for treatment of diseases associated with iron overload and severe anemias; intended for subcutaneous administration.
Orally available ENPP1 small-molecule inhibitor
An orally administered small-molecule inhibitor of ENPP1 designed to reduce inorganic pyrophosphate and restore phosphate balance to promote bone mineralization, under development for hypophosphatasia.
C5-targeted antibody-mimetic fusion protein (once-weekly, subcutaneous)
A protein fusion construct engineered to inhibit Complement component 5 (C5) intended for complement-mediated diseases; formulated for small-volume, once-weekly subcutaneous self-administration.
C5-targeted PEG-conjugated small protein for intravitreal use
A small protein designed to inhibit C5 and conjugated to polyethylene glycol to extend ocular half-life, intended for intravitreal administration in ophthalmic complement-driven diseases.
Long-acting anti-matriptase-2 monoclonal antibody (subcutaneous)
A long-acting monoclonal antibody designed to inhibit matriptase-2 to increase hepcidin levels for treatment of diseases associated with iron overload and severe anemias; intended for subcutaneous administration.
Orally available ENPP1 small-molecule inhibitor
An orally administered small-molecule inhibitor of ENPP1 designed to reduce inorganic pyrophosphate and restore phosphate balance to promote bone mineralization, under development for hypophosphatasia.
Services
Partnerships and collaborative development
Collaboration and co-development agreements to advance product candidates aligned with the company mission; engagement with external discovery and development partners.
Partnerships and collaborative development
Collaboration and co-development agreements to advance product candidates aligned with the company mission; engagement with external discovery and development partners.
Expertise Areas
- Rare disease drug development
- Complement pathway therapeutics
- Hematology
- Metabolic disorder therapeutics
Key Technologies
- Monoclonal antibody discovery and engineering
- Antibody-mimetic fusion protein constructs
- Albumin-binding domain half-life extension
- PEG conjugation for pharmacokinetics